Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation

Anne-France Le Rolle; Thang K. Chiu; Zhaoshi Zeng; Jinru Shia; Martin R. Weiser; Philip B. Paty; Vi K. Chiu

doi:10.18632/oncotarget.6818

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Priority Research Papers:

Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation

Anne-France Le Rolle _, Thang K. Chiu, Zhaoshi Zeng, Jinru Shia, Martin R. Weiser, Philip B. Paty and Vi K. Chiu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:2159-2174. https://doi.org/10.18632/oncotarget.6818

Metrics: PDF 2475 views | HTML 5874 views | ?

Abstract

Anne-France Le Rolle1, Thang K. Chiu3, Zhaoshi Zeng4, Jinru Shia5, Martin R. Weiser4, Philip B. Paty4 and Vi K. Chiu1,2

1 Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, CA, USA

2 Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA

3 Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA, USA

4 Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

5 Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Correspondence to:

Vi K. Chiu, email:

Keywords: KRAS, embryonic stem cell-like program, colorectal cancer, cancer plasticity, EMT

Received: June 27, 2015 Accepted: December 30, 2015 Published: January 04, 2016

Abstract

Colorectal cancer is the third most frequently diagnosed cancer worldwide. Prevention of colorectal cancer initiation represents the most effective overall strategy to reduce its associated morbidity and mortality. Activating KRAS mutation (KRASmut) is the most prevalent oncogenic driver in colorectal cancer development, and KRASmut inhibition represents an unmet clinical need. We apply a systems-level approach to study the impact of KRASmut on stem cell signaling during human colon cancer initiation by performing gene set enrichment analysis on gene expression from human colon tissues. We find that KRASmut imposes the embryonic stem cell-like program during human colon cancer initiation from colon adenoma to stage I carcinoma. Expression of miR145, an embryonic SC program inhibitor, promotes cell lineage differentiation marker expression in KRASmut colon cancer cells and significantly suppresses their tumorigenicity. Our data support an in vivo plasticity model of human colon cancer initiation that merges the intrinsic stem cell properties of aberrant colon stem cells with the embryonic stem cell-like program induced by KRASmut to optimize malignant transformation. Inhibition of the embryonic SC-like program in KRASmut colon cancer cells reveals a novel therapeutic strategy to programmatically inhibit KRASmut tumors and prevent colon cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6818

Publication Alerts

Priority Research Papers:

Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation

Abstract